Therapeutic Potentials of Poly (ADP-Ribose) Polymerase 1 (PARP1) Inhibition in Multiple Sclerosis and Animal Models: Concept Revisiting.

Wang, Yan; Pleasure, David; Deng, Wenbin; Guo, Fuzheng

Wang, Yan; Pleasure, David; Deng, Wenbin; Guo, Fuzheng.

Afiliación

Wang Y; Department of Neurology, School of Medicine, University of California, Davis, CA, 95817, USA.
Pleasure D; Institute for Pediatric Regenerative Medicine, UC Davis School of Medicine/Shriners Hospitals for Children, Sacramento, CA, USA.
Deng W; Department of Neurology, School of Medicine, University of California, Davis, CA, 95817, USA.
Guo F; Institute for Pediatric Regenerative Medicine, UC Davis School of Medicine/Shriners Hospitals for Children, Sacramento, CA, USA.

Adv Sci (Weinh) ; 9(5): e2102853, 2022 02.

Article en En | MEDLINE | ID: mdl-34935305

Asunto(s)

Esclerosis Múltiple; Poli(ADP-Ribosa) Polimerasa-1; Animales; Reparación del ADN; Humanos; Esclerosis Múltiple/tratamiento farmacológico; Poli(ADP-Ribosa) Polimerasa-1/antagonistas & inhibidores; Poli ADP Ribosilación

Palabras clave

PARP1; demyelination; inflammatory demyelinating disease; multiple sclerosis; neuroinflammation; neuronal/axonal degeneration; poly-ADP ribosylation

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Poli(ADP-Ribosa) Polimerasa-1 / Esclerosis Múltiple Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Adv Sci (Weinh) Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google